

## EXHIBITION

Space will be available for commercial vendors' displays/exhibits during the symposium. Interested parties should contact the Scientific Secretariat by email: [ISTR2019@iaea.org](mailto:ISTR2019@iaea.org)

## SYMPOSIUM WEB PAGE

Detailed information on administrative procedures including participation, submission of papers, registration and grants is provided on the symposium web site: <https://www.iaea.org/events/istr-2019>

Please include reference number IAEA-CN-276 in all communications.

## IAEA CONTACT PERSONS

### Scientific matters, submission of papers:

Mr Joao Osso Junior (Scientific Secretary)  
Department of Physical and Chemical Sciences  
Tel.: +43 1 2600 21748  
Email: [ISTR2019@iaea.org](mailto:ISTR2019@iaea.org)

### Participation, grants and administrative matters:

Ms Julie Zellinger  
Division of Conference and Document Services  
IAEA-CN-276; EVT1805040  
Tel.: +43 1 2600 21321  
Email: [J.Zellinger@iaea.org](mailto:J.Zellinger@iaea.org)

CN-276



[iaea.org/events/istr-2019](https://www.iaea.org/events/istr-2019)



## INTERNATIONAL SYMPOSIUM ON TRENDS IN RADIOPHARMACEUTICALS

#ISTR2019

IAEA Headquarters  
Vienna International Centre  
Austria

28 October – 1 November 2019



## BACKGROUND

Progress in nuclear medicine has always been closely linked to the development of new radiopharmaceuticals and the efficient production of relevant radioisotopes.

Impressive progress has been made in radioisotope production technologies over the years. This has allowed broader access to several new radionuclides. Special attention has recently been given to theranostic radioisotopes and  $\alpha$ -emitting radionuclides for in-vivo therapy.

The field of radiopharmaceuticals has witnessed continuous evolution thanks to the immense contributions of scientists from diverse disciplines such as radiochemistry, inorganic chemistry, organic chemistry, organometallic chemistry, biochemistry, molecular biology, physiology and pharmacology. Several milestones can be cited in the trajectory of this growth, which include continuing development of technetium-99m radiopharmaceuticals, automated synthesis of fluorine-18 labelled compounds, radiopharmaceuticals labelled with generator eluted gallium-68, labelled peptides and monoclonal antibodies for accurate diagnosis and treatment of tumours.

The concept of theranostic radioisotopes, that combines the diagnosis and therapy properties of one radioisotope or a pair of similar radioisotopes, may provide an attractive paradigm for future development of medical applications of radionuclides. Biomolecules developed for specific molecular target and labelled with theranostic radionuclides provide clinically significant information for diagnosis, suitability of radionuclide therapy, dosimetry and post therapy planning, making personalised medicine a reality.

## OBJECTIVES

The main objective of the ISTR-2019 Symposium is to provide all the professionals working in the fields of production of medical radioisotopes and radiopharmaceuticals an international forum for discussing the most recent developments in the field. Various topics will be covered during the Symposium including development, production, and uses of diagnostic, therapeutic, and theranostic radioisotopes and radiopharmaceuticals, and related licensing and health regulatory issues. Education, certification and training methodologies will also be addressed.

## TOPICS

- Production of medical radioisotopes, radionuclide generators, and radiopharmaceuticals
- Quality control and quality assurance of radioisotopes and radiopharmaceuticals
- Pre-clinical evaluation of radiopharmaceuticals
- Good Manufacturing Practices and health regulatory aspects for production of medical radioisotopes and radiopharmaceuticals
- Radiopharmacy Chapter in Pharmacopoeias
- Education, including e-learning, certification and training methodologies for professionals involved in radiopharmacy.

## AUDIENCE

The Symposium will bring together (radio)chemists, (radio)pharmacists, biologists, physicists, technologists, medical researchers, policy makers and health regulators, educators and other professionals working in the fields of production and uses of medical radioisotopes and radiopharmaceuticals.

## KEY DEADLINES

<b>28 February 2019</b>	Submission of abstract (including Forms A and B)
<b>28 February 2019</b>	Submission of grant applications (Form C)
<b>31 March 2019</b>	Notification of acceptance of abstract
<b>31 March 2019</b>	Submission of accepted full paper

Any participant not submitting an abstract should submit Participation Form A through the appropriate authority as soon as possible (see conference web page for further details).

## REGISTRATION

No registration fee is charged. Limited funds are available to assist certain participants. Approved grants will usually cover only part of the cost of attendance. Please see the conference web page for details on how to register.

## LANGUAGE

The symposium will be held in English.